P - Contraindicated in pregnancy
L - Contraindicated in lactation
Voglibose, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
Information Not Available
Flatulence; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity.
Information Not Available
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 years; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).
May enhance effects of other antidiabetics including insulin.
Information Not Available
Oral
Diabetes mellitus
Adult: 200-300 mcg tid.
Elderly: Initiate at lower doses.
Should be taken with food. (Take just before meals.)
Contraindicated in pregnancy
Contraindicated in lactation
Information Not Available
Information Not Available
Inflammatory bowel disease; GI obstruction or patients predisposed to it; conditions which may deteriorate as a result of increased gas formation eg, hernia; severe ketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM.
Oral
Store below 30°C.
Oral
Store below 30°C.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.